Physician profile
Robin Roberts
NPI 1679527048
$4,985.71
in general payments reported to CMS, 2019-2025
31 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $884 · 2020: $434 · 2021: $638 · 2022: $433 · 2023: $713 · 2024: $700 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,596.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $700.57 | 2019-2025 | Sotyktu |
| Abbvie INC. | $595.48 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $533.78 | 2019-2025 | |
| Coloplast Corp | $389.56 | 2021 | |
| Lilly USA, LLC | $347.11 | 2019-2025 | Olumiant, Ebglyss, Taltz |
| Genzyme Corporation | $334.74 | 2020-2025 | |
| Almirall LLC | $252.99 | 2019-2023 | Klisyri |
| Ucb, INC. | $190.85 | 2020-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $188.68 | 2025 | Zoryve |
| Janssen Biotech, INC. | $180.52 | 2019-2025 | Simponi Aria, Tremfya, Stelara |
| Dermavant Sciences, INC. | $159.94 | 2023-2024 | Vtama |
| Verrica Pharmaceuticals INC. | $147.77 | 2023-2024 | Ycanth |
| Sun Pharmaceutical Industries INC. | $131.27 | 2020-2025 | |
| Incyte Corporation | $125.03 | 2022-2025 | Opzelura |
| Pfizer INC. | $118.25 | 2019-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $97.63 | 2019-2025 | Nemluvio |
| Glaxosmithkline, LLC. | $90.77 | 2019-2021 | |
| Amgen INC. | $79.40 | 2021-2025 | Otezla |
| Leo Pharma INC. | $52.72 | 2023-2025 | Adbry |
| Nobelpharma America, LLC | $48.64 | 2024 | |
| Medimetriks Pharmaceuticals, INC. | $34.75 | 2025 | Clindacin Etz, Neo-Synalar |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $34.02 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $25.55 | 2024 | Dupixent |
| Vyne Pharmaceuticals INC. | $24.28 | 2020 | |
| Dusa Pharmaceuticals, INC. | $19.15 | 2019 | |
| Organon LLC | $17.17 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.01 | 2025 | Spevigo |
| Lnhc, INC | $14.88 | 2025 | Zelsuvmi |
| Merck Sharp & Dohme LLC | $13.11 | 2019 | |
| Mylan Pharmaceuticals INC. | $12.89 | 2019 | |
| Prugen, INC. Pharmaceuticals | $8.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.